Clinical radiobiology of glioblastoma multiforme: Estimation of tumor control probability from various radiotherapy fractionation schemes;Klinische Strahlenbiologie des Glioblastoms: Schätzung der Tumorkontrollwahrscheinlichkeit von verschiedenen Radiotherapie-Fraktionierungsschemata

Strahlentherapie und Onkologie

Volumn 190, Issue 10, 2014, Pages 925-932

  Pedicini, Piernicola ^a   Fiorentino, Alba ^b   Simeon, Vittorio ^a   Tini, Paolo ^c   Chiumento, Costanza ^a   Pirtoli, Luigi ^c   Salvatore, Marco ^d   Storto, Giovanni ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d IRCCS SDN   (Italy)

Author keywords

Accelerated proliferation; Glioblastoma multiforme; Hypofractionation; Intrinsic radiosensitivity; Repopulation kinetics

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL STUDY; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RADIATION DOSE; RADIOBIOLOGY; RADIOSENSITIVITY; BIOLOGICAL MODEL; BRAIN NEOPLASMS; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER SIMULATION; EVALUATION STUDY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; RADIATION DOSE FRACTIONATION; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VALIDATION STUDY;

BRAIN NEOPLASMS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DOSE FRACTIONATION; GLIOBLASTOMA; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RADIATION TOLERANCE; RADIOTHERAPY, CONFORMAL; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84919873901     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0638-9     Document Type: Article

References (32)

1. Balducci M, Apicella G, Manfrida S, Mangiola A, Fiorentino A, Azario L, D’Agostino GR, Frascino V, Dinapoli N, Mantini G, Albanese A, de Bonis P, Chiesa S, Valentini V, Anile C, Cellini N (2010) Single-Arm Phase II Study of Conformal Radiation Therapy and Temozolomide plus fractionated Stereotactic Conformal Boost in High grade Gliomas. Strahlen Onkol 186(10):558–564
2. Balducci M, Chiesa S, Diletto B, D’Agostino GR, Mangiola A, Manfrida S, Mantini G, Albanese A, Fiorentino A, Frascino V, De Bari B, Micciche F, De Rose F, Morganti AG, Anile C, Valentini V (2012) Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro Oncol 14(1):79–86
3. Balducci M, Fiorentino A, De Bonis P, Chiesa S, Mangiola A, Mattiucci GC, D’Agostino GR, Frascino V, Mantini G, Alitto AR, Colosimo C, Anile C, Valentini V (2013) Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. Strahlen Onkol 189(11):926–931
4. Bao S, Wu Q, Mc Lendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760
5. Buckner JV, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O’Fallon JR, North Central Cancer Treatment Group 93–72-52, Southwest Oncology Group 9503 Trials (2006) Phase III Trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93–72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24(24):3871–3879
6. Ciammella P, Galeandro M, D’Abbiero N, Podgornii A, Pisanello A, Botti A, Cagni E, Iori M, Iotti C (2013) Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience. Clin Neurol Neurosurg 115(9):1609–1614
7. Collett D (1994) Modelling survival data-in medical research. Chapman and Hall, London, pp 22–26
8. Daşu A, Toma-Daşu I, Fowler JF (2003) Should single distributed parameters be used to explain the steepness of tumour control probability curves? Phys Med Biol 48:387–397
9. Efron B (1981) Censored data and the bootstrap. J Am Stat Ass 76:312–319
10. Fietkau R, Putz F, Lahmer G, Semrau S, Buslei R (2013) Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastomamultiforme at the present time?: a word of caution. Strahlenther Onkol 189(12):993–995
11. Guckenberger M, Mayer M, Buttmann M, Vince GH, Sweeney RA, Flentje M (2011) Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. Strahlen Onkol 187(9):548–554
12. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003
13. Jones TS, Holland EC (2012) Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene 31:1995–2006
14. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, Radany EH, Lichter AS, Sandler HM (1999) Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79–88
15. Massaccesi M, Ferro M, Cilla S, Balducci M, Deodato F, Macchia G, Valentini V, Morganti AG (2013) Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1). Int J Clin Oncol 18(5):784–791
16. Mizumoto M, Okumura T, Ishikawa E, Yamamoto T, Takano S, Matsumura A, Oshiro Y, Ishikawa H, Sakurai H, Tsuboi K (2013) Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Technical considerations based on experience at a single institution. Strahlenther Onkol 189(8):656–663
17. Morganti AG, Balducci M, Salvati M, Esposito V, Romanelli P, Ferro M, Calista F, Digesù C, Macchia G, Ianiri M, Deodato F, Cilla S, Piermattei A, Valentini V, Cellini N, Cantore GP (2010) A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. Int J Radiat Oncol Biol Phys 77(1):92–97
18. Nakagawa K, Aoki Y, Fujimaki T, Tago M, Terahara A, Karasawa K, Sakata K, Sasaki Y, Matsutani M, Akanuma A (1998) High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40(5):1141–1149
19. Okunieff P, Morgan D, Niemierko A et al (1995) Radiation dose-response of human tumor. Int J Radiat Oncol Biol Phys 32:1227–1237
20. Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, Lambert C, Leblanc R, Del Maestro R, Guiot MC, Shenouda G (2009) Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy. Int J Radiat Oncol Biol Phys 73(2):473–478
21. Pedicini P (2013) In regard to Pedicini et al. Int J Radiat Oncol Biol 87(5):858
22. Pedicini P, Nappi A, Strigari L, Jereczek-Fossa BA, Alterio D, Cremonesi M, Botta F, Vischioni B, Caivano R, Fiorentino A, Improta G, Storto G, Benassi M, Orecchia R, Salvatore M (2012) Correlation between EGFR expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat Oncol 7:143
23. Pedicini P, Caivano R, Strigari L, Benassi M, Fiorentino A, Fusco V (2013) In regard to Miralbell et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 85(1):10–11
24. Pedicini P, Fiorentino A, Improta G, Nappi A, Salvatore M, Storto G (2013) Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma. Clin Transl Oncol 15(11):919–924
25. Pedicini P, Strigari L, Benassi M (2013) Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 85(5):e231–e237
26. Roberts SA, Hendry JH (1998) A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity. Int J Radiat Oncol Biol Phys 41(3):689–699
27. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60(3):853–860
28. Stupp R, Mason W, Van der Bent M, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblatoma. N Engl J Med 352(10):987–996
29. Terasaki M, Eto T, Nakashima S, Okada Y, Ogo E, Sugita Y, Tokutomi T, Shigemori M (2011) A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. J Neurooncol 102(2):247–253
30. Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J, Kresel JJ, Curran WJ, Diaz A, Mehta MP, Radiation Therapy Oncology Group Trial 98-03 (2009) Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys 73(3):699–708
31. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network (2010) An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17(1):98–110
32. Walker MD, Strike TA (1976) An evaluation of methyl-CCNU, BCNU and radiotherapy in the treatment of malignant glioma. Proc Am Assoc Cancer Res 17:63